Good Evening Market Enthusiast,

The Watch is Over: The Dam Has Burst 🌊

For months, we have kept a laser focus on a specific sector disruptor, tracking every data point as it moved from theoretical projection to realized milestone. We’ve watched the charts tighten and the sentiment shift from simple curiosity to absolute conviction. Today marks the end of our quiet observation period. Things are no longer just "looking better", they are accelerating at a pace that suggests the chance for early participation is rapidly disappearing.

We are officially activating our coverage of 60 Degrees Pharmaceuticals (NASDAQ: SXTP).

(1)

If you have been waiting for the definitive moment to focus on this specialized powerhouse, you are looking at it. The current level of ~$4.15 represents a staggering disconnect between perceived value and the sheer magnitude of the commercial and clinical breakthroughs hitting the wire right now. (8)

The Analysts are Sounding the Alarm: 320%+ Potential 👀 (7)(8)(9)

While the broader market is just starting to wake up to the revenue trajectory, primary research desks are aggressively re-writing their playbooks. The consensus average price target has moved to $17.60, representing a potential move of over 320% from current levels.

Even more telling is the massive shift from one of the industry's most influential analysts. This firm recently vaulted their personal target from $6.00 all the way to $24.00. This is not a minor adjustment; it is a total re-evaluation of what this entity is worth based on their validated pipeline and commercial expansion. When experts shift their targets by 4x, it is a clear signal that the underlying fundamentals have reached a critical mass that can no longer be ignored.

A Validated Platform with an Unmatched "Moat" 🏰 (1)(2)(3)(4)(5)(6)
 

This is a rare case where a company already holds the "Holy Grail" of milestones—U.S. FDA approval—yet is priced like a speculative startup. Their lead product, ARAKODA, is not an idea; it is a commercially available medication.
 

• Broad-Spectrum Dominance: ARAKODA is the only prophylactic therapy that provides protection against all stages of malaria.
• Convenience as a Catalyst: Unlike daily alternatives, ARAKODA offers a convenient weekly dosing schedule.
• Government Backing: The product was discovered by the Walter Reed Army Institute of Research and funded by the United States Army Medical & Materiel Activity.
• Massive IP Protection: The company holds three Orange Book listed patents that do not expire until December 2035, with dozens of other patents filed or pending.
   

The Convergence of Three Massive Catalysts 💥(1)(2)(3)(4)(5)(6)
 

The reason the pressure is building so intensely right now is the simultaneous convergence of three distinct revenue drivers:
 

1. The Consumer Access Revolution 
The company just secured a landmark partnership with Runway Health, a travel-focused telehealth platform. Starting April 2, 2026, international travelers can access ARAKODA through direct, physician-led online consultations and home delivery. This bypasses traditional pharmacy friction and places the product directly in the hands of the 1.7 million travelers who need it annually.

2. Doubling the Force for 2026 
Encouraging results from a 6-month commercial pilot showed an undeniable increase in product sales and prescriber demand. In response, the company is doubling its inside sales representatives for 2026. They are also engaging with GoodRx to provide wider coverage and savings, ensuring they capture the maximum possible market share at the point of sale.

3. Owning the Babesiosis Market 
The company is currently executing three clinical trials to address Babesiosis—a tick-borne infection with zero currently FDA-approved treatments.
 

• Orphan Drug Status: The FDA granted Orphan Drug status for this indication in 2024.
• Serious Need: The FDA recently acknowledged that babesiosis meets the criteria for a "serious or life-threatening disease".
• Expanding Research: To accelerate data output, the company is adding more clinical sites to its ongoing studies, aiming to prove efficacy in a patient market exceeding 1.2 million people.
   

The New Botanical Revenue Lane 🧬 (1)(2)(3)(4)(5)(6)
 

On January 28, 2026, the company signaled its intent to dominate a whole new sector by exercising an exclusive license for Australian Chestnut Extract. This extract contains castanospermine, which has been shown to modulate carbohydrate metabolism and glucose levels. The company is now commencing the regulatory process to secure access to the U.S. market as a non-prescription botanical product. This represents a massive, untapped revenue stream that is currently being valued at zero by the broader market.
 

The Path to 2027: Profitability in Sight 🔎 (1)(2)(3)(4)(5)(6)
 

The leadership team is not guessing, they are executing a military-grade business plan. Led by CEO Geoffrey Dow, PhD, who has over 20 years of experience in tropical disease product development, the company is targeting profitability by 2027. With $4.1 million in cash as of late 2025 and a clear runway, they have the resources to hit these milestones.

The Verdict 🏁 (5)(6)(8)(9)

The bridge between a $4.15 valuation and a $24.00 analyst target is being built in real-time by these breakthroughs. The indicators are screaming that the window is closing.

The question is simple: Will you be ready when the next data readout or revenue surge hits the headlines?

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://finance.yahoo.com/news/60-degrees-pharmaceuticals-exercises-license-130100998.html
2. https://finance.yahoo.com/news/60-degrees-pharmaceuticals-announces-partnership-13010089

5.html
3. https://finance.yahoo.com/news/60-degrees-pharmaceuticals-announces-expansion-130100157

.html
4. https://60degreespharma.com/
5. https://bit.ly/4c515SP
6. https://bit.ly/45Cmb7e
7. https://finance.yahoo.com/quote/SXTP/
8. https://finance.yahoo.com/quote/SXTP/history/
9. https://finance.yahoo.com/quote/SXTP/analyst-insights/

Paid Promotion. Momentum Media LLC has been hired for a period beginning on 02/01/2026 and ending on 02/01/2026 (the “Campaign”) to publicly disseminate information about 60 Degrees Pharmaceuticals, Inc. (SXTP:US). Momentum Media LLC has been compensated $30,000.00 and are owed an additional $0 for the Campaign. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.